{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:38:41Z","timestamp":1793140721434,"version":"4.5.0"},"reference-count":42,"publisher":"Georg Thieme Verlag KG","issue":"05","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Levodopa-induced dyskinesia (LID) is a common motor complication of levodopa therapy in patients with Parkinson's disease (PD). Doxycycline is a widely used and inexpensive tetracycline with anti-inflammatory properties.<\/jats:p><jats:p>\n          Objective\u2003To evaluate the efficacy and safety of doxycycline in patients with PD and LID.<\/jats:p><jats:p>\n          Methods\u2003This was an open-label, uncontrolled, single-arm, single-center, phase 2 proof-of-concept study in patients with PD with functional impact of dyskinesia, which used levodopa three times daily, in a movement disorders clinic in Brazil. Participants were treated with doxycycline 200\u2009mg\/day for 12 weeks, with evaluations at baseline, week 4, and week 12 of treatment. The primary outcome measure was the change from baseline in the Unified Dyskinesia Rating Scale (UDysRS) total score at week 12, evaluated by two blinded raters. Key secondary outcomes measures were OFF time and ON time with troublesome dyskinesia in the PD home diary.<\/jats:p><jats:p>\n          Results\u2003Eight patients with PD were treated and evaluated. Doxycycline 200\u2009mg\/day reduced the UDysRS total score at week 12, compared with baseline (Friedman \u03c72\u2009=\u20099.6; p\u2009=\u20090.008). Further, doxycycline reduced the ON time with troublesome dyskinesia (Friedman \u03c72\u2009=\u200910.8; p\u2009=\u20090.004) without worsening parkinsonism. There were no severe adverse events, and dyspepsia was the commonest event.<\/jats:p><jats:p>\n          Conclusion\u2003In this preliminary, open-label and uncontrolled trial, doxycycline was effective in reducing LID and safe after a 12-week treatment. Further well-designed placebo-controlled clinical trials with a longer duration and a larger number of participants are needed.<\/jats:p><jats:p>\n          Clinical trial registration\u2003https:\/\/ensaiosclinicos.gov.br, identifier: RBR-1047fwbf<\/jats:p>","DOI":"10.1055\/s-0043-1768668","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T22:50:38Z","timestamp":1685573438000},"page":"460-468","source":"Crossref","is-referenced-by-count":8,"title":["Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study"],"prefix":"10.1055","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-5710","authenticated-orcid":false,"given":"Bruno Lopes","family":"Santos-Lobato","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neuroci\u00eancias e Ci\u00eancias do Comportamento, Ribeir\u00e3o Preto SP, Brazil."},{"name":"Universidade Federal do Par\u00e1, Faculdade de Medicina, Laborat\u00f3rio de Neuropatologia Experimental, Bel\u00e9m PA, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2915-6637","authenticated-orcid":false,"given":"Manuelina Mariana Capellari Macruz","family":"Brito","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neuroci\u00eancias e Ci\u00eancias do Comportamento, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4433-702X","authenticated-orcid":false,"given":"\u00c2ngela Vieira","family":"Pimentel","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neuroci\u00eancias e Ci\u00eancias do Comportamento, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-6993","authenticated-orcid":false,"given":"R\u00f4mulo Torres Oliveira","family":"Cavalcanti","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neuroci\u00eancias e Ci\u00eancias do Comportamento, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4158-7376","authenticated-orcid":false,"given":"Elaine","family":"Del-Bel","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Odontologia de Ribeir\u00e3o Preto, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2402-2709","authenticated-orcid":false,"given":"Vitor","family":"Tumas","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neuroci\u00eancias e Ci\u00eancias do Comportamento, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"GBD 2016 Parkinson's Disease Collaborators","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"B R Bloem","year":"2021","journal-title":"Lancet"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/mds.26125","article-title":"Clinical spectrum of levodopa-induced complications","volume":"30","author":"C C Aquino","year":"2015","journal-title":"Mov Disord"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"20140190","DOI":"10.1098\/rstb.2014.0190","article-title":"Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?","volume":"370","author":"M Bortolanza","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.expneurol.2016.09.013","article-title":"Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease","volume":"286","author":"G Mulas","year":"2016","journal-title":"Exp Neurol"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s12035-021-02625-1","article-title":"Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson's Disease: Focus on Neuroinflammation","volume":"59","author":"B L Santos-Lobato","year":"2022","journal-title":"Mol Neurobiol"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00702-021-02447-4","article-title":"Levodopa-induced dyskinesias in Parkinson's disease increase cerebrospinal fluid nitric oxide metabolites' levels","volume":"129","author":"B L Santos-Lobato","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"issue":"34","key":"ref8","doi-asserted-by":"crossref","first-page":"57316","DOI":"10.18632\/oncotarget.17622","article-title":"An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease","volume":"8","author":"M Kong","year":"2017","journal-title":"Oncotarget"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14728214.2020.1763954","article-title":"Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update","volume":"25","author":"S AlShimemeri","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuropharm.2018.05.035","article-title":"Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease","volume":"147","author":"T H Johnston","year":"2019","journal-title":"Neuropharmacology"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s12640-015-9592-2","article-title":"Doxycycline Suppresses Microglial Activation by Inhibiting the p38 MAPK and NF-kB Signaling Pathways","volume":"29","author":"F V Santa-Cec\u00edlia","year":"2016","journal-title":"Neurotox Res"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaneurol.2016.0022","article-title":"Exploring the Association Between Rosacea and Parkinson Disease: A Danish Nationwide Cohort Study","volume":"73","author":"A Egeberg","year":"2016","journal-title":"JAMA Neurol"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/idj.12221","article-title":"Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases","volume":"66","author":"L M Golub","year":"2016","journal-title":"Int Dent J"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/glia.22496","article-title":"Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model","volume":"61","author":"M Lazzarini","year":"2013","journal-title":"Glia"},{"issue":"13","key":"ref15","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1111\/bph.15439","article-title":"Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats","volume":"178","author":"M Bortolanza","year":"2021","journal-title":"Br J Pharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"105650","DOI":"10.1016\/j.nbd.2022.105650","article-title":"Striatal Synaptic Dysfunction in Dystonia and Levodopa-Induced Dyskinesia","volume":"166","author":"M Scarduzio","year":"2022","journal-title":"Neurobiol Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.brainresbull.2018.02.007","article-title":"Doxycycline prevents and reverses schizophrenic-like behaviors induced by ketamine in mice via modulation of oxidative, nitrergic and cholinergic pathways","volume":"139","author":"B Ben-Azu","year":"2018","journal-title":"Brain Res Bull"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"617085","DOI":"10.3389\/fphar.2020.617085","article-title":"Contributive Role of TNF-\u03b1 to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson's Disease","volume":"11","author":"M Dos Santos Pereira","year":"2021","journal-title":"Front Pharmacol"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/mds.27077","article-title":"Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model","volume":"32","author":"T Chotibut","year":"2017","journal-title":"Mov Disord"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"729961","DOI":"10.3389\/fneur.2021.729961","article-title":"Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease","volume":"12","author":"J F Baizabal-Carvallo","year":"2021","journal-title":"Front Neurol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neuroscience.2020.02.030","article-title":"The Link between Gut Dysbiosis and Neuroinflammation in Parkinson's Disease","volume":"432","author":"J F Baizabal-Carvallo","year":"2020","journal-title":"Neuroscience"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3389\/fphar.2019.00738","article-title":"Doxycycline for Alzheimer's Disease: Fighting \u03b2-Amyloid Oligomers and Neuroinflammation","volume":"10","author":"C Balducci","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"41755","DOI":"10.1038\/srep41755","article-title":"Repurposing doxycycline for synucleinopathies: remodelling of \u03b1-synuclein oligomers towards non-toxic parallel beta-sheet structured species","volume":"7","author":"F Gonz\u00e1lez-Liz\u00e1rraga","year":"2017","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"105256","DOI":"10.1016\/j.nbd.2021.105256","article-title":"Doxycycline inhibits \u03b1-synuclein-associated pathologies in vitro and in vivo","volume":"151","author":"A Dominguez-Meijide","year":"2021","journal-title":"Neurobiol Dis"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1532-5415.2004.52109.x","article-title":"A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease","volume":"52","author":"M B Loeb","year":"2004","journal-title":"J Am Geriatr Soc"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/gps.3846","article-title":"A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial","volume":"28","author":"D W Molloy","year":"2013","journal-title":"Int J Geriatr Psychiatry"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","article-title":"Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"13","author":"S Ha\u00efk","year":"2014","journal-title":"Lancet Neurol"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/jnnp-2016-313541","article-title":"Doxycycline in early CJD: a double-blinded randomised phase II and observational study","volume":"88","author":"D Varges","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"15","key":"ref29","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"C G Goetz","year":"2008","journal-title":"Mov Disord"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson's disease","volume":"22","author":"M Emre","year":"2007","journal-title":"Mov Disord"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1128\/AAC.05710-11","article-title":"Pharmacokinetics of doxycycline in adults with cystic fibrosis","volume":"56","author":"P M Beringer","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","article-title":"A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia","volume":"23","author":"R A Hauser","year":"2000","journal-title":"Clin Neuropharmacol"},{"issue":"16","key":"ref33","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.22341","article-title":"The Unified Dyskinesia Rating Scale: presentation and clinimetric profile","volume":"23","author":"C G Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"ref34","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976"},{"issue":"13","key":"ref35","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa1505425","article-title":"Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease","volume":"374","author":"A Berende","year":"2016","journal-title":"N Engl J Med"},{"issue":"03","key":"ref36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/mds.25321","article-title":"Which dyskinesia scale best detects treatment response?","volume":"28","author":"C G Goetz","year":"2013","journal-title":"Mov Disord"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2018.08.018","article-title":"Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale","volume":"58","author":"A Makkos","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.parkreldis.2015.09.044","article-title":"What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?","volume":"21","author":"T A Mestre","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","article-title":"ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial","volume":"74","author":"R Pahwa","year":"2017","journal-title":"JAMA Neurol"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.27131","article-title":"Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)","volume":"32","author":"W Oertel","year":"2017","journal-title":"Mov Disord"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"645706","DOI":"10.3389\/fneur.2021.645706","article-title":"Amantadine ER (Gocovri\u00ae) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease","volume":"12","author":"R A Hauser","year":"2021","journal-title":"Front Neurol"},{"issue":"05","key":"ref42","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mds.21897","article-title":"Placebo influences on dyskinesia in Parkinson's disease","volume":"23","author":"C G Goetz","year":"2008","journal-title":"Mov Disord"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1768668.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T22:52:23Z","timestamp":1685573543000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1768668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":42,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2023,5,31]]},"published-print":{"date-parts":[[2023,5]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1768668","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}